 DNCB has been in use
for a variety of medical purposes for 70 years. Thousands of HIV infected
patients in the USA and elsewhere have been treating themselves with DNCB for many years,
and there is evidence to support the long-term effectiveness and safety of DNCB treatment.
Pilot studies have
demonstrated the clinical effectiveness and absence of significant adverse effects of DNCB
therapy in HIV patients.
Controlled clinical
trials have confirmed both the effectiveness and safety of DNCB therapy in HIV disease.
When an established DNCB
protocol is used, overdoses occur only occasionally, are easily treated, and do not lead
to infections.
The theoretical basis for
the effectiveness of DNCB in HIV disease is now understood.
There are currently only
three alternatives to treatment with DNCB:
(1) No treatment
(2) Treatment with HAART, and
(3) Preventive vaccines.
With no treatment, HIV
disease leads in most cases to AIDS and then to death.
Treatment with HAART may
lead to severe problems with antiretroviral drugs, including serious side effects,
ineffectiveness due to HIV mutations and multidrug resistance, very demanding medication
schedules and very high cost. It is estimated that at least one third of HIV-infected
patients cannot take or do not benefit from antiretroviral drugs for reasons other than
their high cost.
The prospect for a
preventive vaccine in the next ten years is not encouraging 28.
Even if HAART were
completely effective, over 95% of people infected with HIV worldwide cannot benefit from
it because of its very high cost.
For those who can afford and
tolerate HAART, DNCB appears to enhance HAART's efficacy.
|
